Skip to search formSkip to main contentSkip to account menu

GYKI 14451

Known as: GYKI 14,451, GYKI-14,451, GYKI-14451 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1994
1994
Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin.
1992
1992
In vitro inhibition of blood coagulation by tripeptide aldehydes--a retrospective screening study focused on the stable D-MePhe-Pro-Arg-H.H2SO4.
A series of peptide aldehydes synthetized in our institute during the last 15 years were screened to detect their inhibitory… 
Highly Cited
1990
Highly Cited
1990
Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H.
D-Phe-Pro-Arg-H sulfate (GYKI-14166) is a highly active and selective inhibitor of thrombin both in vitro and in vivo. Recent… 
1984
1984
GYKI 14,451, a synthetic tripeptide inhibitor of thrombin: "in vitro" and "in vivo" studies.
The search for new compounds active in blood coagulation with different properties to classical anticoagulants, e.g. heparin, has… 
1982
1982
Design and synthesis of peptide inhibitors of blood coagulations.
Inhibition of blood coagulation by peptide aldehydes has been studied. Amino acid sequences were assembled from the P1-P2 portion… 
1981
1981
GYKI 14,451, a synthetic tripeptide inhibitor of thrombin: activity on platelet aggregation and arachidonic acid metabolism.
1981
1981
Studies on the antithrombotic action of Boc-D-Phe-Pro-Arg-H (Gyki 14,451).
Review
1980
Review
1980
New strategies in the development of anti-atherosclerotic drugs.
The results of several recently completed trials of cardiovascular prevention, by the use of hypolipidemic or anti-platelet… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)